EE41 Cost-Effectiveness of Anti-BCMA CAR T-Cell Therapy in Triple-Class Refractory Multiple Myeloma

Abstract

Idecabtagene vicleucel (ide-cel), an anti-BCMA chimeric antigen receptor T-cell (CAR-T) therapy (list price $419,500), was approved in 2021 by the US FDA for triple-class refractory multiple myeloma (MM). Another anti-BCMA CAR T-cell therapy, ciltecabtagene autoleucel (cilta-cel), is undergoing FDA review. We evaluated the cost-effectiveness of ide-cel and cilta-cel (assuming price parity with ide-cel).